T-cell prolymphocytic leukemia
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| T-cell-prolymphocytic leukemia Classification and external resources | |
| ICD-O: | 9834/3 |
|---|---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and predilection for blood, bone marrow, lymph nodes, liver, spleen, and skin involvement.[1] T-PLL is a rare leukemia, primarily affecting adults over the age of 30. It represents 2% of all small lymphocytic leukemias in adults.[2] Other names include: T-cell chronic lymphocytic leukemia, "Knobby" type of T-cell leukemia, T-prolymphocytic leukemia/T-cell lymphocytic leukemia[1]
Clinical Features
Due to the systemic nature of this disease, leukemic cells can be found in peripheral blood, lymph nodes, bone marrow, spleen, liver, skin.[1]
Etiology
It is postulated that the originating cell line for this disease is a mature (post-thymic) T-cell.[1]
Clinical Presentation
Patients typically have systemic disease at presentation, including hepatosplenomegaly, generalized lymphadenopathy, and skin infiltrates.[1]
Laboratory Findings
A high lymphocyte count (> 100 x 109/L)along with anemia and thrombocytopenia are common findings. HTLV-1 serologies are negative, and serum immunoglobins are within normal limits with no paraproteins present.[1]
Morphology
In the peripheral blood, T-PLL consists of medium-sized lymphocytes with single nucleoli and basophilic cytoplasm with occasional blebs or projections. The nuclei are usually round to oval in shape, with occasional patients having cells with a more irregular nuclear outline that is similar to the cerebriform nuclear shape seen in Sézary syndrome.[3] A small cell variant comprises 20% of all T-PLL cases, and the Sézary cell-like (cerebriform) variant is seen in 5% of cases.[3]
Marrow involvement is typically diffuse with morphology similar to what is observed in peripheral blood.[1] In the spleen, the leukemic cell infiltrate both the red pulp and white pulp, and lymph node involvement is typically diffuse through the paracortex.[1]. Skin infiltrates are seen in 20% of patients, and the infiltrates are usually dense and confined to the dermis and around the skin appendages.[2]
Molecular Findings
Immunophenotype
T-PLL has the immunophenotype of a mature (post-thymic) T-lymphocyte, and the neoplastic cells are typically positive for pan-T antigens CD2, CD3, and CD7 and negative for TdT and CD1a. The immunophenotype CD4+/CD8- is present in 60% of cases, the CD4+/CD8+ immunophenotype is present in 25%, and the CD4-/CD8+ immunophenotype is present in 15% of cases.[2]
Genetic Findings
Clonal TCR gene rearrangements for the γ and δ chains are typically found. The most frequent chromosomal abnormality is the inversion of chromosome 14, specifcally inv 14(q11;q32). This is found in 80% of cases, while 10% of cases show a reciprocal translocation of chromosome 14 (t(14;14)(q11;q32)). [4]
[5] Also, abnormalities of chromosome 8 are seen approximately 75% of patients, including idic (8p11), t(8;8)(p11-12;q12), and trisomy 8. [6]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. IARC Press: Lyon 2001
- ↑ 2.0 2.1 2.2 Matutes E, Brito-Babapulle V, Swansbury J, et al (1991). "Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia". Blood 78 (12): 3269-74. PMID 1742486.
- ↑ 3.0 3.1 Matutes E, Garcia Talavera J, O'Brien M, Catovsky D (1986). "The morphological spectrum of T-prolymphocytic leukaemia". Br. J. Haematol. 64 (1): 111-24. PMID 3489482.
- ↑ Brito-Babapulle V, Catovsky D (1991). "Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia". Cancer Genet. Cytogenet. 55 (1): 1-9. PMID 1913594.
- ↑ Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D (1998). "Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization". Cancer Genet. Cytogenet. 103 (2): 110-6. PMID 9614908.
- ↑ Sorour A, Brito-Babapulle V, Smedley D, Yuille M, Catovsky D (2000). "Unusual breakpoint distribution of 8p abnormalities in T-prolymphocytic leukemia: a study with YACS mapping to 8p11-p12". Cancer Genet. Cytogenet. 121 (2): 128-32. PMID 11063795.
WikiDoc Research Resources for T-cell prolymphocytic leukemia | |
|---|---|
| Articles on T-cell prolymphocytic leukemia | Most recent articles on T-cell prolymphocytic leukemia • Most cited articles on T-cell prolymphocytic leukemia • Review articles on T-cell prolymphocytic leukemia • Articles on T-cell prolymphocytic leukemia in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on T-cell prolymphocytic leukemia | Powerpoint slides on T-cell prolymphocytic leukemia • Images of T-cell prolymphocytic leukemia • Photos of T-cell prolymphocytic leukemia • Podcasts & MP3s on T-cell prolymphocytic leukemia • Videos on T-cell prolymphocytic leukemia |
| Evidence Based Medicine Regarding T-cell prolymphocytic leukemia | Cochrane Collaboration on T-cell prolymphocytic leukemia • Bandolier on T-cell prolymphocytic leukemia • TRIP on T-cell prolymphocytic leukemia |
| Cost Effectiveness of T-cell prolymphocytic leukemia | Cost Effectiveness of T-cell prolymphocytic leukemia |
| Clinical Trials Involving T-cell prolymphocytic leukemia | Ongoing Trials on T-cell prolymphocytic leukemia at Clinical Trials.gov • Trial results on T-cell prolymphocytic leukemia • Clinical Trials on T-cell prolymphocytic leukemia at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding T-cell prolymphocytic leukemia | US National Guidelines Clearinghouse on T-cell prolymphocytic leukemia • NICE Guidance on T-cell prolymphocytic leukemia • NHS PRODIGY Guidance • FDA on T-cell prolymphocytic leukemia • CDC on T-cell prolymphocytic leukemia |
| Textbook Information on T-cell prolymphocytic leukemia | Books and Textbook Information on T-cell prolymphocytic leukemia |
| Pharmacology Resources on T-cell prolymphocytic leukemia | Dosing of T-cell prolymphocytic leukemia • Drug interactions with T-cell prolymphocytic leukemia • Side effects of T-cell prolymphocytic leukemia • Allergic reactions to T-cell prolymphocytic leukemia • Overdose information on T-cell prolymphocytic leukemia • Carcinogenicity information on T-cell prolymphocytic leukemia • T-cell prolymphocytic leukemia in pregnancy • Pharmacokinetics of T-cell prolymphocytic leukemia • |
| Genetics, Pharmacogenomics, and Proteinomics of T-cell prolymphocytic leukemia | Genetics of T-cell prolymphocytic leukemia • Pharmacogenomics of T-cell prolymphocytic leukemia • Proteomics of T-cell prolymphocytic leukemia |
| Newstories on T-cell prolymphocytic leukemia | T-cell prolymphocytic leukemia in the news • Be alerted to news on T-cell prolymphocytic leukemia • News trends on T-cell prolymphocytic leukemia |
| Commentary on T-cell prolymphocytic leukemia | Blogs on T-cell prolymphocytic leukemia |
| Patient Resources on T-cell prolymphocytic leukemia | Patient resources on T-cell prolymphocytic leukemia • Discussion groups on T-cell prolymphocytic leukemia • Patient Handouts on T-cell prolymphocytic leukemia • Directions to Hospitals Treating T-cell prolymphocytic leukemia • Risk calculators and risk factors for T-cell prolymphocytic leukemia |
| Healthcare Provider Resources on T-cell prolymphocytic leukemia | Symptoms of T-cell prolymphocytic leukemia • Causes & Risk Factors for T-cell prolymphocytic leukemia • Diagnostic studies for T-cell prolymphocytic leukemia • Treatment of T-cell prolymphocytic leukemia |
| Continuing Medical Education (CME) Programs on T-cell prolymphocytic leukemia | CME Programs on T-cell prolymphocytic leukemia |
| International Resources on T-cell prolymphocytic leukemia | T-cell prolymphocytic leukemia en Espanol • T-cell prolymphocytic leukemia en Francais |
| Business Resources on T-cell prolymphocytic leukemia | T-cell prolymphocytic leukemia in the Marketplace • Patents on T-cell prolymphocytic leukemia |
| Informatics Resources on T-cell prolymphocytic leukemia | List of terms related to T-cell prolymphocytic leukemia |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
